Avinger Inc. reported positive two-year clinical data from the pivotal VISION study of its Lumivascular technology. The VISION study was designed to evaluate the Redwood City, Calif.-based company's Pantheris system, which received FDA clearance last year. (See Medical Device Daily, March 10, 2016.) Interim results from 55 patients in the study were released at the Leipzig Interventional Course conference.
Alphabet Inc.'s Verily Life Sciences LLC is set to receive $800 million in funding from Temasek, a Singapore-based investment company. A majority of the investment will be funded in the coming days, and the remainder will come in the second half of this year. In exchange for the funding, Temasek will receive a minority stake in the Mountain View, Calif.-based company, which was once Google's life sciences division. This will be the first time Verily has taken funding from an outside investor, said Carolyn Wang, a spokesperson for Verily. The company primarily derives its funding...
Alphabet Inc.'s Verily Life Sciences LLC is set to receive $800 million in funding from Temasek, a Singapore-based investment company. A majority of the investment will be funded in the coming days, and the remainder will come in the second half of this year. In exchange for the funding, Temasek will receive a minority stake in the Mountain View, Calif.-based company, which was once Google's life sciences division.
Heart Test Labs Inc. (HTL) has raised about $12 million in its most recent funding round. The company is developing Myovista, an electrocardiography device, that it said could potentially fill the "diagnostic gap" in heart disease. HTL is currently vying for approval of Myovista in Europe. "We're on the cusp of going to market [in Europe]," Andrew Simpson, executive chairman of Westlake, Texas-based HTL, told Medical Device Daily. "Fingers crossed, we expect to get CE mark approval this quarter. This round is going to be used to build up the sales capacity of the company...
Heart Test Labs Inc. (HTL) has raised about $12 million in its most recent funding round. The company is developing Myovista, an electrocardiography device, that it said could potentially fill the "diagnostic gap" in heart disease. HTL is currently vying for approval of Myovista in Europe.
Johnson & Johnson Corp. (J&J) forecast lower-than-expected 2017 sales but managed to beat Wall Street expectations for its 4Q16 earnings. In addition, the New Brunswick, N.J.-based company said it could potentially sell off its diabetes care businesses amid disappointing sales. Tuesday's news was mixed at best. While 4Q16 adjusted earnings per share of $1.58 exceeded analysts' consensus estimates of $1.56, J&J drew criticism for its soft 2017 guidance. The firm forecast 2017 adjusted earnings of $6.93 to $7.08 per share – below the average analyst estimate of $7.11 per share. Joshua Jennings, an analyst with...
Johnson & Johnson Corp. (J&J) forecast lower-than-expected 2017 sales but managed to beat Wall Street expectations for its 4Q16 earnings. In addition, the New Brunswick, N.J.-based company said it could potentially sell off its diabetes care businesses amid disappointing sales.
Amedica Corp. is looking to raise $4.5 million through a public offering slated to close on Tuesday. The funding raise comes in the middle of the Salt Lake City-based company's bid to obtain clearance for its Valeo cancellous-structure ceramic cervical (C+Csc) implant. Amedica has been waiting for the FDA to green light the device for nearly two years now. (See Medical Device Daily, Feb. 13, 2015.)
Banyan Biomarkers Inc. is getting $7 million in funding from in vitro diagnostics specialist Biomérieux SA to help develop a blood test for traumatic brain injury (TBI). In addition, the Marcy L'etoile-France-based company has also obtained the right to commercialize Banyan's TBI tests with its Vidas immunoassays range platform. Banyan's test uses two brain specific protein biomarkers (Banyan UCH-L1 and Banyan GFAP) that rapidly appear in the blood after a brain injury. The San Diego-based company was founded in 2002 and is a spin off from the University of Florida. "We are excited about the...
